alexa In Vivo Effects Of Subcutaneous Inositol Hexaphosphate (IP6) On Tumor Growth In A Murine Bladder Cancer Model
ISSN: 2471-8556

Oncology & Cancer Case Reports
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

15th World Congress on CANCER THERAPY, BIOMARKERS & CLINICAL RESEARCH
December 05-07, 2016 Philadelphia, USA

Ali Hajiran
West Virginia University School of Medicine, USA
Posters & Accepted Abstracts: Oncol Cancer Case Rep
DOI: 10.4172/2471-8556.C1.003
Abstract
Introduction: Inositol Hexaphosphate (IP6) is a naturally occurring carbohydrate found in food sources high in fiber content. We have previously demonstrated the in vitro anti‐cancer effects of IP6 against bladder cancer. Based on those results we evaluated the potential of IP6 in an in vivo murine bladder cancer model. Methods: Sixty female athymic nude mice were randomized to four groups (15/group). Mice received 1 x 107 UM‐UC‐6 bladder cancer cells in a 0.1 cc volume in the right thigh (Day 0). Mice then received the following subcutaneous treatments: Saline, IP6 0.5 mM, IP6 1.0 mM and IP6 2.0 mM on days 1, 3, 5, 7, 9, and 11. All animals were examined three times weekly for the incidence and growth of tumor. Tumor volume is expressed as Mean + Standard Deviation. Statistical significance was determined by ANOVA. Results: All IP6 treatment groups significantly reduced tumor growth compared to the saline control (ANOVA, P < 0.001) on experimental days 9 through 14. All IP6 groups reduced tumor volume equally compared to control and there was no dose response effect noted. Conclusions: This represents the first report of the effects of IP6 in a mouse bladder cancer model. We are currently investigating orally administered IP6 in mice in preparation for proposing a Phase II clinical trial to evaluate the safety and clinical utility of this agent.
Biography

Email: [email protected]

image PDF   |   image HTML
 

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version